Researchers have utilized the natural activity of the Bcl-2-interacting mediator of cell death (BIM), which interacts with BCL-2 and possesses one of the most potent BH3 death domains in the BCL-2 protein family, to attempt to restore BH3-dependent cell death in resistant hematological cancers. The gene discussed is BCL2; the disease is hematopoietic and lymphoid cell neoplasm.